martes, 8 de noviembre de 2022

Hybrid immunity from vaccination and Omicron BA.1 or BA.5 breakthrough infections exhibits cross-reactive efficacy against BA.2.75

Hybrid immunity from vaccination and Omicron BA.1 or BA.5 breakthrough infections exhibits cross-reactive efficacy against BA.2.75

No hay comentarios:

Publicar un comentario